Evoke Pharma Inc reports results for the quarter ended June 30 - Earnings Summary

• Evoke Pharma Inc EVOK.OQ reported a quarterly adjusted loss of 62 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -93 cents. The lone analyst forecast for the quarter was for a loss of 30 cents per share.

• Revenue rose 47.1% to $3.75 million from a year ago; analysts expected $3.80 million.

• Evoke Pharma Inc's reported EPS for the quarter was a loss of 62 cents​.

• The company reported a quarterly loss of $1.57 million.

• Evoke Pharma Inc shares had risen by 89.6% this quarter and gained 11.5% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

This summary was machine generated from LSEG data August 14 at 11:39 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)